SCHEMBL5458514

SCHEMBL5458514

NC(=O)c1c(NC(=O)Nc2ccc(OCc3ccccc3)cc2)sc2c1CCCC2

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.61
MAPT P10636 4/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
ALDH1A1 P00352 1/20 0.59
LMNA P02545 1/20 0.59
GAA P10253 1/20 0.59
THRB P10828 1/20 0.58
TP53 P04637 3/20 0.57
RXFP1 Q9HBX9 2/20 0.57
TLR2 O60603 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
TDP1 Q9NUW8 1/20 0.55
CASP3 P42574 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
POLB P06746 1/20 0.53
TNIK Q9UKE5 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467129 0.88 TNIK (0.50) FLT3MAPTMEN1KMT2ATHRB
SCHEMBL5465704 0.87 NPC1 (0.51) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL5455976 0.87 KMT2A (0.64) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL5450860 0.85 MEN1 (0.78) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL5448370 0.83 MEN1 (0.68) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL8290385 0.83 MEN1 (0.74) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL5455906 0.82 FLT3 (0.74) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL4234573 0.80 FLT3 (0.72) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL5455812 0.80 MAPT (0.58) FLT3MAPTMEN1KMT2AALDH1A1
SCHEMBL5453363 0.79 FLT3 (0.71) FLT3MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MAPT 21/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.